logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
NGNE
Neurogene Inc.
33.88
2 x 23.89
2 x 40.42
bid
ask
+
2.43
7.73%
2 @ 04:00 PM
34.17 +0.29 (0.86%)
Ytd64.47%
1y76.55%
31.43
day range
34.35
15.93
52 week range
37.27
Open31.89Prev Close31.45Low31.43High34.35Mkt Cap535.37M
Vol677.22KAvg Vol180.08KEPS-4.55P/EN/AForward P/E-4.85
BetaN/AShort Ratio7.15Inst. Own110.72%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1150-d Avg28.97200-d Avg23.631yr Est52.80

NGNE News

benzinga.com
Neurogene Prices $125M Public Offering At $30/Share, $29.999999 Pre‑Funded Warrants

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medici

Neurogene Inc. Announces Pricing of $125 Million Public Offering
businesswire.com
Neurogene Inc. Announces Pricing of $125 Million Public Offering

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

benzinga.com
Neurogene Reveals Proposed Public Offering; No Size Disclosed

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medici

Neurogene Inc. Announces Proposed Public Offering
businesswire.com
Neurogene Inc. Announces Proposed Public Offering

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Transcript
seekingalpha.com
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Tra

Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Tra

Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
gurufocus.com
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medic
benzinga.com
Neurogene Announces Updated Data From Phase 1/2 Clinical Trial Evaluating NGN-401 Gene Therapy For T

47 total developmental milestones gained across 10 participants, with durable treatment effect and n

Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
businesswire.com
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring

benzinga.com
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $70 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy

benzinga.com
Neurogene Completes Dosing In Embolden Registrational Trial Of NGN-401, Investigational Gene Therapy

Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to str